Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Silence, Karen" or (type exact bookEditor and editor="Silence, Karen")

Mark
CD70 and PD-L1 in anaplastic thyroid cancer : promising targets for immunotherapy

Karen Zwaenepoel, Julie Jacobs, Astrid De Meulenaere (UGent) , Karen Silence, Evelien Smits, Vasiliki Siozopoulou, Esther Hauben, Christian Rolfo, Sylvie Rottey (UGent) and Patrick Pauwels

(2017) HISTOPATHOLOGY. 71(3). p.357-365
Mark
- journalArticle
- A1
- open access
Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy

Julie Jacobs, Vanessa Deschoolmeester, Christian Rolfo, Karen Zwaenepoel, Jolien Van den Bossche, Christophe Deben, Karen Silence, Hans de Haard, Christophe Hermans, Sylvie Rottey (UGent) , et al.

(2017) ONCOTARGET . 8(43). p.74058-74067
Mark
Phase I dose-escalation study of the anti-CD70 antibody ARGX-110 in advanced malignancies

Philippe Aftimos, Christian Rolfo, Sylvie Rottey (UGent) , Fritz Offner (UGent) , Dominique Bron, Marie Maerevoet, Jean-Charles Soria, Mahan Moshir, Torsten Dreier, Luc Van Rompaey, et al.

(2017) CLINICAL CANCER RESEARCH. 23(21). p.6411-6420
Mark
- conference
- C3
Clinical response observed in a phase I study in T cell lymphoma patients treated with anti-CD70 SIMPLE antibody ARGX-110

Jean-Marie Michot, Marie Maerevoet, Philippe Georges Aftimos, Sylvie Rottey (UGent) , Christian Diego Rolfo, Fritz Offner (UGent) , Luc Van Rompaey, Mahan Moshir, Hans de Haard, Karen Silence, et al.

(2016) JOURNAL OF CLINICAL ONCOLOGY. 34(15, suppl.).
Mark
Depleting MET-expressing tumor cells by ADCC provides a therapeutic advantage over inhibiting HGF/MET signaling

Anna Hultberg, Virginia Morello, Leander Huyghe, Natalie De Jonge, Christophe Blanchetot, Valérie Hanssens, Gitte de Boeck, Karen Silence, Els Festjens, Raimond Heukers, et al.

(2015) CANCER RESEARCH. 75(16). p.3373-3383
Mark
ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade

Karen Silence, Torsten Dreier, Mahan Moshir, Peter Ulrichts, Sofie ME Gabriels, Michael Saunders, Harald Wajant, Peter Brouckaert (UGent) , Leander Huyghe (UGent) , Tim Van Hauwermeiren, et al.

(2014) MABS. 6(2). p.523-532
Mark
- conference
- C3
A phase I first-in-human study of ARGX-110, a monoclonal antibody targeting CD70, a receptor involved in immune escape and tumor growth in patients with solid and hematologic malignancies

Ahmad Awada, Christian D Rolfo, Sylvia Rottey, Laure Ysebrant de Lendonck, Wilfrled A Schroyens, Fritz Offner (UGent) , Karen Silence, Torsten Dreier, Mahan Moshir, Hans de Heard, et al.

(2014) JOURNAL OF CLINICAL ONCOLOGY. 32(15, suppl.).
Mark
Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis

Ken Coppieters (UGent) , Torsten Dreier, Karen Silence, Hans de Haard, Marc Lauwereys, Peter Casteels, Els Beirnaert, Heidi Jonckheere, Christophe Van De Wiele (UGent) , Ludovicus Staelens, et al.

(2006) ARTHRITIS AND RHEUMATISM. 54(6). p.1856-1866

Academic Bibliography

CD70 and PD-L1 in anaplastic thyroid cancer : promising targets for immunotherapy

Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy

Phase I dose-escalation study of the anti-CD70 antibody ARGX-110 in advanced malignancies

Clinical response observed in a phase I study in T cell lymphoma patients treated with anti-CD70 SIMPLE antibody ARGX-110

Depleting MET-expressing tumor cells by ADCC provides a therapeutic advantage over inhibiting HGF/MET signaling

ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade

A phase I first-in-human study of ARGX-110, a monoclonal antibody targeting CD70, a receptor involved in immune escape and tumor growth in patients with solid and hematologic malignancies

Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis

Contents

Support

Contact